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Renal cell carcinoma (RCC) less than 3 cm in diameter rarely metastasizes. In this report, we present the
case of a metastatic RCC in which the primary tumor was 1.6 cm. We further review the relevant
literature to highlight this rare but important clinical presentation.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Small renal masses (SRMs) are believed to be of indolent pa-
thology. In a retrospective review by Thompson et al, only 1 out of
781 patients with a tumor diameter less than 3 cm presented with
metastatic disease.1 Indeed, protocols for active surveillance of
renal masses are often limited to clinical T1a tumors. When SRMs
are found in the presence ofmetastatic disease, it introduces unique
challenges regarding treatment andmanagement. Here, we present
the case of a man who initially presented with metastatic disease
and a cT1a renal mass.
Case presentation
A 65 year-old gentleman with a history notable for heavy
smoking and stable lung nodules presented to his primary care
physician with limited mobility due to numbness and pain in his
left chest wall, shoulder, and hand of 6 months duration. He sub-
sequently underwent a CT scan of the chest for surveillance of his
lung nodules, which were unchanged from prior. However, many
lytic lesions were visualized in the thoracic spine, and he was
referred to the neurosurgical service at our institution for
evaluation.
Further review of the imaging showed pathologic fractures with
tumor compression of the thecal sac and spinal cord at T3, T4, T5,all renal mass; CN, cytore-
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Inc. This is an open access article uand T11 (Fig. 1A). Lytic lesions were also observed in the lumbar
spine (L1), left eighth rib, and right iliac wing, concerning for
metastatic disease. In addition, a small (1.6 cm  1.4 cm) enhancing
renal mass was demonstrated on the lateral aspect of the left upper
pole, raising suspicion for RCC (Fig. 1B). There were no pathologi-
cally enlarged abdominal or pelvic lymph nodes.
The patient was taken to the operating room for multi-level
decompression and fusion of T1-L1 vertebrae and resection of the
epidural tumor at T4, T5, and T11. Pathology of the tumor revealed a
metastatic clear cell renal cell carcinoma, cT1aN0M1. He was rec-
ommended stereotactic body radiation therapy to improve local
control of his spinal metastasis. Cytoreductive nephrectomy (CN) of
the primary renal mass was considered but ultimately deferred
given the patient’s extensive metastatic disease burden. Several
management options were discussed, ranging from standard ther-
apies (high-dose IL-2, tyrosine-kinase inhibitors) to clinical trials
(CheckMate 214 e nivolumab with ipilimumab versus sunitinib
monotherapy; NCT02231749).
Discussion
Metastatic disease is rarely observed in the setting of SRMs,1 a
phenomenon associated with greater acceptance of active sur-
veillance as a management option for these lesions. As this case
report demonstrates, however, SRMs may in rare instances
possess metastatic potential, and patients must therefore be
counseled regarding the possibility of progression during
surveillance.
The prognosis of RCC is largely tied to the presence or absence of
metastatic disease. In the absence of metastasis, patients with
localized RCC can be deﬁnitively treated with surgery and have a
ﬁve-year disease-speciﬁc survival of 80e95%.2 This ﬁgure drops tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. (A) T1-weighted MRI of the thoracic and lumbar spine demonstrating metastatic tumor compression of the thecal sac and spinal cord at T3-T5 (green arrow) and T11 (red
arrow). (B) CT with contrast of the abdomen demonstrating 1.6 cm left renal mass (red arrow).
R. Alam et al. / Urology Case Reports 4 (2016) 59e6060less than 10% for patients with metastasis, although several groups
have demonstrated increased survival in individuals with isolated
metastatic lesions amenable to resection.3 The vast majority of
patients with metastasis, however, present with widespread dis-
ease, and the median overall survival has historically been only 10
to 15 months with cytokine therapy.2
Themore recent advent of targeted agents, such as sunitinib, has
changed the landscape of treatment for metastatic RCC, andmedian
overall survival has increased to beyond two years in this popula-
tion.2 While CN was associated with a demonstrable survival
beneﬁt during the era of cytokine therapy, the role of CN remains
unclear in the current setting. In a contemporary population treated
with targeted therapy, Heng and colleagues recently demonstrated
a survival beneﬁt after CN in patients who met less than four of the
six International Metastatic Renal Cell Carcinoma Database Con-
sortium (IMDC) criteria (hemoglobin below the lower limit of
normal, corrected calcium above the upper limit of normal [ULN],
neutrophils above the ULN, platelets above the ULN, Karnofsky
performance status <80%, and time from diagnosis to treatment
<1 year), suggesting that a therapeutic beneﬁt exists for appro-
priately selected patients.4 The fractional percentage of tumor
volume (FPTV) removed during cytoreduction also appears to have
a predictive role in the therapeutic effect of CN. Speciﬁcally,
resection of small primary tumors derives minimal beneﬁt in the
setting of a large metastatic burden.5 As systemic therapies evolve,
it is important that we continue investigate the role of surgery andother local treatments to provide the optimal overall care to these
patients.
Conclusion
This report represents a rare case of distant metastatic disease in
the setting of a 1.6 cm renal mass. Medical therapies remain the
mainstay of treatment, whereas the role of cytoreductive ne-
phrectomy remains unclear.
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